1. Home
  2. /
  3. Projects

Brazil

Part of Change 2.0

Actionable market intelligence, including vaccine demand forecast/scenarios, generated to strategically guide manufacturers and partners in their planning for introduction in high burden countries. The objectives include: 1. Strategic assessment of appropriate market-shaping interventions, 2.Stakeholder and decision process mapping , 3.Demand dynamics understanding and realistic market forecast development, 4. Commercialization strategy support for lead candidate(s).

IAVI

1. Understand likely use cases, delivery strategies, target populations, and drivers of preference and adoption; 2. Project demand; 3. Evaluate potential willingness to pay and budget impact; 4. Explore innovative financing mechanisms;

Global impact and cost-effectiveness of tuberculosis interventions

The modelling study compares the population-level impact and cost-effectiveness of TB vaccination with other TB interventions. It models vaccination scale-up in Brazil, India, and South Africa and estimates that vaccination could prevent 15-28% of symptomatic TB episodes by 2050. It provides evidence to inform investment, policy, and planning for future TB vaccine introduction and scale-up.

FAST-TB MOD

FAST-TB population and cost-effectiveness modelling core: This project will accelerate tuberculosis (TB) research translation by using mathematical modelling to address key priority questions as part of FAST TB, linking an expanded state-of-the-art modelling framework with country level data and cross consortium communication around new TB treatment regimens, diagnostics and other interventions.

Creating evidence to support tuberculosis (TB) national and global decision-makers in reducing the global burden of TB

In strong collaboration, we (India, South Africa, Brazil, Indonesia, UK) will create evidence to strengthen capacity and sustainably support high tuberculosis (TB) burden countries (HBC) and global decision-makers in reducing the global burden of TB, by using modelling tools to address key questions on drug-resistant (DR-)TB, new TB vaccines and other interventions, and extend and apply a state-of-the-art TB model, to estimate the relative health, cost-effectiveness, and budget impact, of new and existing interventions, as well as their optimal combination.
Click to copy link of this header Menu